Abstract. To examine the pathological features and prognosis of different molecular subtypes of breast cancer, the clinical data of 892 breast cancer patients were retrospectively analyzed and divided into four subtypes according to hormone receptor expression in breast cancer tissue: Her-2 overexpression, luminal A, luminal B and basal-like subtypes. The pathological data and prognosis of these subtypes were compared. Of the 892 breast cancer patients, there were 46 cases (5.2%) with Her-2 overexpression-type, 698 cases (78.3%) with luminal A-type, 38 cases (4.3%) with luminal B-type and 110 patients (12.2%) with basal-like-type. Immunohistochemistry was used to identify the progesterone and estrogen receptors in the tumor tissues. The χ 2 test was used to verify the measurement data. The Cox proportional hazard regression model was used for the univariate and multivariate analyses. Results showed there was no statistical difference for lymphatic metastasis among the various molecular subtypes of breast cancer (P>0.05). The distant metastatic rate of patients with Her-2-type breast cancer was significantly higher compared to patients with the other three subtypes (P<0.05). The difference in local recurrence among molecular subtypes was not significantly significant (P>0.05). Lymph node metastasis, age and different molecular subtypes were found to have an impact on patient overall survival (OS) and disease-free survival (DFS). Her-2 overexpression-type breast cancer patients had the lowest 9-year DFS and 7-year OS compared to the other subtypes (P<0.05). Thus, Her-2-type was associated with the worst prognosis. In conlusion, the molecular typing of breast cancer has important clinical value in prognosis estimation and is expected to affect breast cancer treatment approaches.
Introduction
Treatment for breast cancer is mainly guided by clinical staging and TNM staging, which are based on the size of the primary tumor and the degree of metastasis to regional lymph nodes and blood circulation (1) . Prognosis of breast cancer may differ even with common characteristics in their pathological type or clinical stage (2) . Therefore, individualized treatment may depend on the molecular characteristics of breast cancer (3) . Previous theories in 'breast cancer genotyping' (1) suggested that different molecular subtypes are associated with different prognoses (4) . In this study, a retrospective analysis was conducted of the pathological data and prognosis of breast cancer patients (n=892) admitted to our hospital between January 2000 and December 2009.
Materials and methods
General information. Patients (n=892) who had invasive breast cancer and received surgical treatment in our hospital (from January 2009 to December 2011) were selected for this study. The study was approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University. The study included 882 females and 10 males with a maximum age of 86 years, minimum age of 21 years and mean age of 56.2±21.3 years. In total, 712 patients received modified radical mastectomy, 89 patients received radical mastectomy, 55 patients received modified and extended radical mastectomy, and 36 patients received breast-conserving surgery. Immunohistochemical methods. The ready-to-use non-biotin EliVision™ two-step method was used to reveal the progesterone receptor (PR) and estrogen receptor (ER) subtypes in tumor tissues. Immunohistochemistry was performed using the DAB developing process. The paraffin-embedded tissue was cut into serial sections of 4-µm, mounted on glass slides that were treated with 3-aminopropyltriethoxy-silane (APES) acetone solution, and baked in an oven at 60˚C for 1 h. Slides were dewaxed and incubated at room temperature with 3% H 2 O 2 for 10 min. A microwave (100˚C) was used to repair the antigens for 15 min after the inactivation of endogenous peroxidase. Ready-to-use monoclonal antibodies were used as the primary antibodies. The ready-to-use broad-spectrum EliVision plus kits, DAB color-developing agents and antibodies were purchased from Fuzhou Maixin Biotechnology Development Co., Ltd. (Fujian, China). A positive expression of PR and ER was manifested as ≥10% of tumor cells with the expression of labeled hormone receptors. According to the expression of Her-2, PR and ER in tumor tissues, breast cancer was divided into four molecular subtypes: Her-2 overexpression, luminal A, luminal B and basal-like.
Follow-up. Until December 2011, patients in the study were followed up by letter, telephone or clinic visit to confirm their prognosis. Definite diagnosis of recurrence was made by image diagnosis or clinical manifestation. In this study, 872 patients had follow-up results, with a follow-up rate of 97.8% and mean follow-up period of 46.2±13.7 months.
Statistical analysis. The SPSS16.0 statistical software was used for statistical analysis. The χ 2 test was used to verify the measurement data. The Cox proportional hazard regression model was used to perform multivariate analysis to determine the survival analysis: inclusion, α=0.05 and exclusion, α=0.1. P<0.05 indicates a statistically significant difference.
Results

Molecular typing results of breast cancer patients.
Breast cancer patients were divided into four subtypes: 46 patients (5.2%) with Her-2 overexpression, 698 patients (78.3%) with luminal A, 38 patients (4.3%) with luminal B and 110 patients (12.2%) with basal-like subtypes of breast cancer.
Clinicopathological characteristics of breast cancer patients.
Lymph node metastasis was not significantly different among the various molecular subtypes of breast cancer (P>0.05). However, patient age, tumor size and clinical stage among the molecular subtypes were statistically significant (P<0.05) ( Table I) .
Distant metastasis and local recurrence of different molecular subtypes of breast cancer. Sixty-two of the 872 patients who were followed up had distant metastasis, including (Table II) .
Univariate analysis of overall survival (OS) and disease-free survival (DFS) in patients with different molecular subtypes of breast cancer.
Univariate analysis results showed that the 7-year DFS and 9-year OS of lymph node-positive patients were both shorter compared to node-negative patients (P<0.05). Her-2 overexpression-type patients had the lowest 9-year DFS and OS among the four molecular subtypes (P<0.05) (Table III) .
Multivariate Cox regression analysis of DFS and OS in patients with different molecular subtypes of breast
cancer. Lymph node metastasis, patient age and different molecular subtypes have an impact on patient DFS and OS.
Compared to the Her-2 overexpression-type, the other three molecular subtypes had a better DFS and OS prognosis (Tables IV and V) .
Discussion
Histomorphological characteristics of tumors are the gold standard for pathological diagnosis, and therefore the basis for clinical treatment. Traditional clinical staging has been significant for determining patient prognosis. However, with new advances in molecular medicine, traditional pathological staging cannot meet the needs of modern cancer diagnosis and treatment (5, 6) . Currently, results of genetic testing methods for breast cancer are inconclusive. Breast cancer is usually divided into four subtypes according to immunohistochemical indicators commonly used in clinical practice: Her-2 overexpression, luminal A, luminal B and basal-like subtypes (7, 8) . This study showed that luminal A-type had the highest constituent ratio in 892 cases of invasive breast cancer patients, while luminal B-type had the lowest constituent ratio; findings that are consistent with the results of previous studies (9) (10) (11) (12) . Age, tumor size and clinical stages among patients with different molecular subtypes were statistically significant (P<0.05). Nevertheless, clinicopathological parameters of breast cancer patients have multiple influencing factors, thus more studies are required to confirm these conclusions. The key to the therapeutic success of breast cancer treatment lies in limiting distant metastasis, which is correlated with molecular typing (13, 14) . The results of this study revealed that the distant metastatic rate of Her-2-type breast cancer patients was significantly higher compared to other subtypes (P<0.05). The local recurrence rate was not significantly different among the molecular subtypes (P>0.05). These results indicate that the molecular typing of breast cancer is of great value in the prognosis and treatment options available for breast cancer patients, particularly gene-targeted therapy for the Her-2 overexpressing-type. The prognosis of patients with breast cancer is also closely correlated with the molecular subtype (15) . This study found that patients with Her-2 overexpression had the lowest 9-year OS and 7-year DFS among all the molecular subtypes. Adjuvant therapy may therefore be necessary for patients overexpressing the Her-2 marker.
Molecular typing of breast cancer may benefit the clinical prediction of tumor response to therapy and patient prognosis (14) . Improvements should be made to existing personalized treatment plans based upon the molecular typing of breast cancer. Additionally, gaining a better understanding and knowledge in this field may prolong survival and improve the quality of life for breast cancer patients. 
